Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma

[1] Leoni LM(2008)Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents Clin Cancer Res 14 309-317

[2] Bailey B(2014)Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Blood 123 2944-2952

[3] Reifert J(2008)Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study J Clin Oncol 26 204-210

[4] Bendall HH(2010)Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study Cancer 116 106-114

[5] Zeller RW(2008)Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma J Clin Oncol 26 4473-4479

[6] Corbeil J(2010)Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development Br J Pharmacol 159 34-48

[7] Elliott G(1998)Chemotherapy of advanced NSCLC and SCLC with bendamustine—a phase II study Pneumologie 52 571-574

[8] Niemeyer CC(2002)CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235-242

[9] Flinn IW(2000)European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 18 317-324

[10] van der Jagt F(1998)Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma Ann Oncol 9 995-1001

[1] Leoni LM(2008)Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents Clin Cancer Res 14 309-317

[2] Bailey B(2014)Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Blood 123 2944-2952

[3] Reifert J(2008)Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study J Clin Oncol 26 204-210

[4] Bendall HH(2010)Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study Cancer 116 106-114

[5] Zeller RW(2008)Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma J Clin Oncol 26 4473-4479

[6] Corbeil J(2010)Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development Br J Pharmacol 159 34-48

[7] Elliott G(1998)Chemotherapy of advanced NSCLC and SCLC with bendamustine—a phase II study Pneumologie 52 571-574

[8] Niemeyer CC(2002)CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235-242

[9] Flinn IW(2000)European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 18 317-324

[10] van der Jagt F(1998)Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma Ann Oncol 9 995-1001